FDA arthritis drug rejection hits Eli Lilly shares https://t.co/zyZo0UTl7R via @FT
— The Propell Group (@ThePropellGroup) April 18, 2017
#healthtech
FDA arthritis drug rejection hits Eli Lilly shares https://t.co/zyZo0UTl7R via @FT
— The Propell Group (@ThePropellGroup) April 18, 2017
#healthtech